| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 08/31/2006 | WO2006090850A1 Benzamide compound |
| 08/31/2006 | WO2006090830A1 Method of producing proanthocyanidin oligomer |
| 08/31/2006 | WO2006090817A1 Indole compound and use thereof |
| 08/31/2006 | WO2006090815A1 Agent for preventing development of prion disease, food additive and feed additive comprising the same |
| 08/31/2006 | WO2006090767A1 PROMOTER OF REGENERATION OF PANCREATIC β CELL, AND PROMOTER OF INSULIN PRODUCTION IN PANCREATIC β CELL |
| 08/31/2006 | WO2006090759A1 Pharmaceutical agent comprising solifenacin |
| 08/31/2006 | WO2006090756A1 Novel preventive or remedy for lipid metabolism disorder, obesity and diabetes and use therefor |
| 08/31/2006 | WO2006090717A1 Quinazoline derivative having tyrosine kinase inhibitory activity |
| 08/31/2006 | WO2006090698A1 Kinase inhibitor and use thereof |
| 08/31/2006 | WO2006090697A1 Therapeutic agent for disease with apoptotic degeneration in eye tissue cell containing pedf and fgf2 |
| 08/31/2006 | WO2006090616A1 Fat cell differentiation regulator |
| 08/31/2006 | WO2006090613A1 Hair cosmetic |
| 08/31/2006 | WO2006090555A1 Akt ACTIVATING AGENT |
| 08/31/2006 | WO2006090494A1 Anticancer agent |
| 08/31/2006 | WO2006090413A1 Novel crystalline form of gefitinib and a process for its preparation |
| 08/31/2006 | WO2006090150A1 Pharmaceutical composition comprising amorphous rosiglitazone |
| 08/31/2006 | WO2006023852A3 Modulators of muscarinic receptors |
| 08/31/2006 | WO2006013193A3 Derivatives of arylsulfonamido-substituted hydroxamic acid as matrix metalloproteinases inhibitors |
| 08/31/2006 | US20060194966 N'-{2-amino-1-(3,5-difluorobenzyl)-3-[(3-; ethylbenzyl)oxy]propyl}-N,N-dipropylisophthalamide; beta-secretase inhibitors; halts or reduces production of A beta peptide from amyloid precursor proteins and reduces or eliminates the formation of beta-amyloid deposits in the brain |
| 08/31/2006 | US20060194883 Mmp expression inhibitor |
| 08/31/2006 | US20060194881 Composition comprising at least one alkanolamide to inhibit megration of langerhans cells and uses therof |
| 08/31/2006 | US20060194872 Diamine derivative, production process therefor and antioxidant |
| 08/31/2006 | US20060194868 Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and /or congestive heart failure |
| 08/31/2006 | US20060194864 Indole derivatives |
| 08/31/2006 | US20060194863 e.g. [(4-Morpholinophenylamino)-methylene]-1,3-dihydro-indol-2-one;tyrosine kinase signal transduction modulators; antiproliferative agents; vision defects, atherosclerosis, restenosis, metabolic disorders, autoimmune diseases |
| 08/31/2006 | US20060194857 Anti-diabetic activity, improves insulin resistance and control the blood glucose level more safely, simulates activity of peroxisome proliferator-activated receptor; (1-{(2E)-3-[3-(Bromomethyl)phenyl]prop-2-en-1-yl}-1H-pyrrol-2-yl)(4-methyl-phenyl)methanone |
| 08/31/2006 | US20060194854 New 2-substituted - 1,3-thiazole compounds |
| 08/31/2006 | US20060194851 Benzofuran compound and medicinal composition containing the same |
| 08/31/2006 | US20060194850 methyl 3-(4-{4-[1-(2-chlorophenyl)ethoxycarbonylamino]-3-isoxazolyl}-benzylsulfanyl)propionate; compounds inhibit the physiological activity of lysophosphatidic acid (LPA); treatment of fibrosis of organs (liver, kidney, lung, and the like), hepatic disease |
| 08/31/2006 | US20060194848 Substituted amine derivatives and methods of use |
| 08/31/2006 | US20060194841 Benzylamine derivative |
| 08/31/2006 | US20060194836 Novel compounds having 4-pyridylalkylthio group as substituent |
| 08/31/2006 | US20060194834 Serotonin receptor antagonist; psychological disorders; Alzheimer's disease |
| 08/31/2006 | US20060194830 Cyclizing 2,6-diaminopyridine in sulfuric acid with malic acid to form 2-amino-7-hydroxy-1,8-naphthyridine; phthalimidating the naphthyridine and replacing the OH with Cl; reducing the product to form the hydroxyindolinone derivative and etherifying with 5-methyl-2-oxo-hexyltriphenylphosphonium halide |
| 08/31/2006 | US20060194828 Vitamin comprising pyroloquinoline quinone and use thereof |
| 08/31/2006 | US20060194818 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| 08/31/2006 | US20060194817 N-{(1S,2R)-1-(3,5-difluorobonzyl)-2-hydroxy-3-[(3-iodobonzyl)amino]propyl}-2-{4-[(methylsulfonyl)amino]phenyl}acetamide; inhibitors of the beta- secretase enzyme useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mamma |
| 08/31/2006 | US20060194811 Pyrimidine derivatives |
| 08/31/2006 | US20060194803 anti-dementia agent which uses a BEC 1 potassium channel inhibitor as the active ingredient; to improve learning disorder |
| 08/31/2006 | US20060194797 Condensed ring compound and use thereof |
| 08/31/2006 | US20060194795 Platelet ADP receptor inhibitors |
| 08/31/2006 | US20060194793 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| 08/31/2006 | US20060194792 1-Cyclic carbonyl-4-(4-quinoline-)-1,4-diazepine or 1-cyclic carbonyl-4-[4-(1H-quinolin-2-{thio}one)-1,4-diazepinone derivatives; retinopathy, adult respiratory distress syndrome, asthma, osteoarthritis, glomerulonephritis, psoriasis, rheumatoid arthritis, and toxic shock syndrome treatment |
| 08/31/2006 | US20060194787 substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamide-derived protease inhibitors which inhibit the likes of cathepsin K; treating osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation |
| 08/31/2006 | US20060194781 Alkyl ether derivatives or salts thereof |
| 08/31/2006 | US20060194778 Serotonin receptor antagonist; psychological disorders; side effect reduction |
| 08/31/2006 | US20060194772 Triamide-substituted heterobicyclic compounds |
| 08/31/2006 | US20060194745 Compounds and methods for inhibiting selectin-mediated function |
| 08/31/2006 | US20060194742 Pyrane derivatives as both ACE- and NEP-inhibitors |
| 08/31/2006 | US20060194731 Using tumor antigens to elicit immune response targeted to cancer cells; immunotherapy |
| 08/31/2006 | US20060194727 Prevention and reduction of blood loss |
| 08/31/2006 | US20060194316 Stromal differentiated neuron-like cells for use in treatment of neurodegenerative, ischemic, spinal cord and ataxic disorders; tissue engineering; regenerative medicine |
| 08/31/2006 | US20060194304 Kit comprising sodium chloride, potassium chloride, guanidinium chloride, sodium perchlorate or other chaotropic salt; and a nonionic detergent of Triton, NP40, Tween, or Syperonic, or MOPS buffer; endotoxin-free; purification, centrifuging, chromatography, filtration; gene therapy |
| 08/31/2006 | US20060194291 Comprising human immunoglobulin g1 fc region, which mediates antibody-dependent cell-mediated cytotoxicity in presence of effector cells more effectively; binds fc gamma receptor iii with better affinity |
| 08/31/2006 | US20060194290 Polypeptide variants with altered effector function |
| 08/31/2006 | US20060194286 Apo-2LI and Apo-3 polypeptides |
| 08/31/2006 | US20060194233 Ligand of the protein "beacon" |
| 08/31/2006 | US20060193929 Method for treating or preventing symptoms associated with menopause |
| 08/31/2006 | US20060193925 such as pioglitazone, troglitazone, rosiglitazone; plant extracts of Ephedrae Herba, Glycyrrhizae Radix and Gypsum Fibrosum in powder form; reduces body weight gain effect |
| 08/31/2006 | US20060193905 Direct cellular energy delivery system |
| 08/31/2006 | US20060193904 Encapsulation of drugs in liposomes; encapsulated transition metal ions and encapsulated drugs, where if the drug is soley doxorubicin, the metal ion is not solely manganese, and the liposomes do not comprise an ionophore |
| 08/31/2006 | US20060193835 Treatment of congestive heart failure |
| 08/31/2006 | US20060193833 Compositions for gene therapy of rheumatoid arthritis including a gene encoding an anti-angiogenic protein or parts thereof |
| 08/31/2006 | US20060193823 Hydrolytically degradable carbamate derivatives of poly (Ethylene Glycol) |
| 08/31/2006 | US20060193790 Promoting whole body health |
| 08/31/2006 | CA2599454A1 Activator for peroxisome proliferator activating receptor d |
| 08/31/2006 | CA2599348A1 Indole compound and use thereof |
| 08/31/2006 | CA2599295A1 Method of producing proanthocyanidin oligomer |
| 08/31/2006 | CA2599150A1 Anticancer agent comprising paclitaxel and a diptheria toxin mutant, crm 197 |
| 08/31/2006 | CA2599115A1 Novel combinational use of sulfonamide compound |
| 08/31/2006 | CA2598864A1 Promoter of regeneration of pancreatic .beta. cell, and promoter of insulin production in pancreatic .beta. cell |
| 08/31/2006 | CA2598278A1 Methods for modulating macrophage proliferation in ocular disease using polyamine analogs |
| 08/30/2006 | EP1696033A2 Pseudomonas exotoxin A-like chimeric immunogens |
| 08/30/2006 | EP1696030A1 TIE ligand homologues |
| 08/30/2006 | EP1696029A1 TIE ligand homologues |
| 08/30/2006 | EP1695986A2 Anti-erb B2 antibodies |
| 08/30/2006 | EP1695983A2 Glucagon-like peptide-1 analogs |
| 08/30/2006 | EP1695982A1 Glycosylation-deficient hepatocyte growth factor |
| 08/30/2006 | EP1695979A2 Gapped 2' modified oligonucleotides |
| 08/30/2006 | EP1695977A2 Spiro [isobenzofuran-1,4'piperidin]-3-ones and 3H-spiroisobenzofuran-1, 4'-piperidines |
| 08/30/2006 | EP1695974A1 1,8-Naphthyridines as CRF antagonists |
| 08/30/2006 | EP1695970A1 Peptides useful for competitive modulation of dipeptidyl peptidase IV catalysis |
| 08/30/2006 | EP1695959A1 Compouds and methods for the inhibition of the expression of VCAM-1 |
| 08/30/2006 | EP1695718A2 Biodegradable polyester and Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
| 08/30/2006 | EP1695716A2 Medicinal compositions containing diuretics and insulin sensitizers |
| 08/30/2006 | EP1695706A1 Medicinal compositions and combinations |
| 08/30/2006 | EP1695705A1 Compounds effecting glucokinase |
| 08/30/2006 | EP1694653A1 Substituted 6-cyclohexylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors |
| 08/30/2006 | EP1694318A1 (s)-2-n-propylamino-5-hydroxytetralin as a d3-agonist |
| 08/30/2006 | EP1513837B1 Thiazole derivatives as phosphodiesterase iv inhibitors |
| 08/30/2006 | EP1436292B1 5-methoxy-8-aryl-¬1,2,4|triazolo¬1,5-a|pyridine derivatives as adenosine receptor antagonists |
| 08/30/2006 | EP1425280B1 Hetero-bicyclic crf antagonists |
| 08/30/2006 | EP1421198A4 Cell-based high-throughput screening methods |
| 08/30/2006 | EP1421086B1 2-(AMINOMETHYL)-TETRAHYDRO-9-OXA-1,3-DIAZA-CYCLOPENTA a|NAPHTHALENYL DERIVATIVES WITH ANTIPSYCHOTIC ACTIVITY |
| 08/30/2006 | EP1414810B1 1,4-disubstituted benzo-fused cycloalkyl urea compounds |
| 08/30/2006 | EP1412343B1 Compounds, which are potent inhibitors of na+/ca2+ exchange mechanism and are useful in the treatment of arrhythmias |
| 08/30/2006 | EP1373250B1 Viologen linked acridine based molecule and process for the preparation thereof |
| 08/30/2006 | EP1318811B1 Cyclopentyl modulators of chemokine receptor activity |
| 08/30/2006 | EP1317429B1 Amidine inhibitors of serine proteases |
| 08/30/2006 | EP1283729B1 Tc and re carbonyl complexes prepared from pertechnetates and perrhenates |